Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: DELT1970 who wrote (2929)	8/1/1999 6:53:00 PM
From: BARRY ALLEN	Read Replies (1) \| Respond to of 4140

More lies...........and cover-up! Still, Sturza's Medical Research analyst Stephen Sabba remains critical of the device, noting that the low levels of hyperopia that it has treated in its studies. He maintains the narrow range of diopters that the device can treat won't produce a significant demand for the product. This is supposedly why AVLN took a short position. Now read their press release! Avalon based its sell/sell short recommendation due to various concerns over potential problems with the clinical data for SNRS' Hyperion (Holmium) Laser and the LTK procedure for Hyperopia submitted to the FDA. These concerns were borne out when a FDA Ophthalmic Devices Panel unanimously rejected SNRS' PMA on July 22, 1999.